The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: a narrative review

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00084580" target="_blank" >RIV/00023001:_____/24:00084580 - isvavai.cz</a>

Výsledek na webu

<a href="https://dom-pubs.pericles-prod.literatumonline.com/doi/epdf/10.1111/dom.15425" target="_blank" >https://dom-pubs.pericles-prod.literatumonline.com/doi/epdf/10.1111/dom.15425</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dom.15425" target="_blank" >10.1111/dom.15425</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: a narrative review

Popis výsledku v původním jazyce

The majority of cases of chronic kidney disease (CKD) worldwide are driven by the presence of type 2 diabetes (T2D), resulting in an increase in CKD rates over the past few decades. The existence of CKD alongside diabetes is associated with increased burden of cardiovascular disease and increased risk of death. Optimal glycaemic control is essential to prevent progression of CKD, but achieving glycaemic targets in people with CKD and diabetes can be challenging because of increased risk of hypoglycaemia and limitations on glucose-lowering therapeutic options. This review considers the challenges in management of T2D in people with impaired kidney function and assesses evidence for use of basal insulin analogues in people with CKD.

Název v anglickém jazyce

The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: a narrative review

Popis výsledku anglicky

The majority of cases of chronic kidney disease (CKD) worldwide are driven by the presence of type 2 diabetes (T2D), resulting in an increase in CKD rates over the past few decades. The existence of CKD alongside diabetes is associated with increased burden of cardiovascular disease and increased risk of death. Optimal glycaemic control is essential to prevent progression of CKD, but achieving glycaemic targets in people with CKD and diabetes can be challenging because of increased risk of hypoglycaemia and limitations on glucose-lowering therapeutic options. This review considers the challenges in management of T2D in people with impaired kidney function and assesses evidence for use of basal insulin analogues in people with CKD.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes, obesity and metabolism

ISSN

1462-8902

e-ISSN

1463-1326

Svazek periodika

26

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

14

Strana od-do

1157-1170

Kód UT WoS článku

001142324000001

EID výsledku v databázi Scopus

2-s2.0-85182459508